However, cyclin B2 overexpression was a poor prognostic biomarker in non-small cell lung cancer [38], bladder cancer [39], invasive breast carcinoma [40], colorectal adenocarcinoma [41]. This evidence concerns the gene CCNB2 and invasive breast carcinoma.